May's 10 most-bought funds
2nd June 2016 12:14
, one of our sister magazine Money Observer's Rated Funds, has once again taken the top position in the most-bought funds on the Interactive Investor platform.
In April it toppled , and has retained top spot once again in May.
The popular fund, managed by contrarian investor Terry Smith, holds £5.8 billion in assets under management. Smith currently has just 27 shares, with 60% held in the US.
Neil Woodford's eponymous open-ended fund, which has regularly topped the list since its launch in June 2014, had to settle for second place. The fund has lost 3.9% over six months to 1 June, but gained 1.9% over the last three months.
Popular passives
Passive funds proved popular in May. Third place in the list was taken by , which splits its money across various equity markets, and also holds global bonds.
Another three passive funds were represented in the top 10. has climbed four spots to take fifth place in May, has jumped three places to seventh place, while moved up by five places to take the eighth spot on the list.
Money Observer Rated Fund climbed four places from April to be the fourth most-bought fund in May.
Elsewhere, has climbed five spots from 11th in April to sixth place in May.
Managed by Linden Thomson, the specialist fund has struggled over the last six months, losing 18.1% as the wider biotech sector took a hit following uncertainty around drug pricing in the US. It is still worth noting, however, that the fund has gained an astonishing 187% over the last five years.
Money Observer Rated Fund dropped by six places from third place in April to ninth in May. took the 10th place.
| May's 10 most-bought funds | |||||
|---|---|---|---|---|---|
| Rank | Fund | IA sector | Change since April | Total return 1m to 1 June (%) | Total return 3yr to 1 June (%) |
| 1 | Fundsmith Equity* | Global | - | 1.9 | 55.3 |
| 2 | CF Woodford Equity Income | UK equity income | - | 1.6 | N/A |
| 3 | Vanguard LifeStrategy 80% Equity | Mixed investment 40-85% shares | 3 | 0.7 | 18.3 |
| 4 | Lindsell Train Global Equity* | Global | 4 | 1.3 | 48.2 |
| 5 | HSBC FTSE 250 Index | UK all companies | 4 | 1.8 | 28.4 |
| 6 | Axa Framlington Biotech* | Specialist | 5 | -0.1 | 57.8 |
| 7 | HSBC FTSE All-Share Index | UK all companies | 3 | 0.6 | 9.4 |
| 8 | Vanguard LifeStrategy 100% Equity | Global | 5 | 0.7 | 19.8 |
| 9 | Artemis Global Income* | Global equity income | -6 | 0.2 | 26.9 |
| 10 | Marlborough UK Micro Cap Growth* | UK smaller companies | -3 | 0.5 | 53.4 |
| *denotes Money Observer Rated Fund | |||||
This article was originally published by our sister magazine Money Observer here.
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Editor's Picks